Skip to main content
An official website of the United States government

Available Agents

Select a column header to sort by Agent Name, Company or Agent Class.

Agent NameNSC NumberCompanyAgent ClassAgent Target/Molecular Target(s)
Alectinib794611GenentechALK inhibitor, tyrosine kinase inhibitorALK, RET
Atezolizumab783608GenentechPD-L1 blocking monoclonal antibodyPD-L1
Avelumab799232EMD Serono, Inc.PD-L1 InhibitorPD-L1
Bevacizumab704865GenentechAnti-angiogenesis inhibitor, monoclonal antibodyVEGF
Blinatumomab765986Amgen IncBispecific T-cell engager (BiTE) monoclonal antibodyCD3, CD19
Capivasertib782347AstraZenecaserine/threonine kinase (AKT) inhibitorAKT 1, AKT 2, AKT 3
Ceralasertib802785AstraZenecaATR kinase inhibitorATR
Cobimetinib781257GenentechMEK1/2 inhibitorMEK1/2
Durvalumab778709AstraZenecaPD-L1 blocking monoclonal antibodyPD-L1, CD80
Ensartinib784729Xcovery Holding Company LLCALK inhibitorALK, TrkA, TrkC, ROS, EphA2, c-MET
Giredestrant840836GenentechSelective estrogen receptor degrader (SERD)ER-targeting therapy
Glofitamab845088GenentechBispecific monoclonal antibodyCD20 expressed on the surface of B cells and CD3 receptor expressed on the surface of T cells.
Inavolisib843575GenentechClass I PI3KαClass I PI3Kα isoform (p110α)
Ipilimumab732442Bristol-Myers Squibbanti-CTLA-4 monoclonal anibodyCTLA-4
Larotrectinib788607BayerTyrosine kinase inhibitorNTRK-1, NTRK-2, NTRK-3 gene fusions; TrkA/B/C fusion proteins
Mirdametinib755770SpringWorks Therapeutics, Inc.MEK1/2 inhibitorMEK1, MEK2
Mogamulizumab791064Kyowa Hakko Kirin Co., Ltd.anti-CCR4 monoclonal antibodyCC chemokine receptor 4 (CCR4)-expressing cells
Nirogacestat811402SpringWorks Therapeutics, Inc.Gamma Secretase InhibitorGamma Secretase
Nivolumab748726Bristol-Myers SquibbPD-1 blocking monoclonal antibodyPD-1
Obinutuzumab793436Genentechanti-CD20 monoclonal antibodyCD20
Olaparib747856AstraZenecaPARP inhibitorPARP-1, PARP-2, PARP-3
Pertuzumab740102Genentechanti-HER2 monoclonal antibodyHER2/neu
Pertuzumab/trastuzumab/ hyaluronidase-zzxf827796GenentechFully human immunoglobulin monoclonal antibodiesHuman epidermal growth factor receptor 2 (HER2, also known as c-erbB-2)
Regorafenib821745BayerL01XE21VEGFR1, VEGFR2, VEGFR3, TIE2, PDGFRB, FGFR1, KIT, RET, RAF1, BRAF
Savolitinib785348AstraZenecaMET kinase inhibitor    MET
SX-682 Syntrix Biosystems, Inc.CXCR1 and CXCR2 inhibitorCXCR1 and CXCR2 expressing cells
Talimogene laherparepvec785349Amgen Inc Genetically modified oncolytic virus
Tiragolumab827799GenentechFully human immunoglobulin monoclonal antibodyT-Cells and natural killer (NK) cell subsets
Trastuzumab688097Genentechanti-HER2 monoclonal antibodyHER2/neu
Trastuzumab and hyaluronidase-oysk827797GenentechFully human immunoglobulin monoclonal antibodyHuman epidermal growth factor receptor 2 (HER2, also known as c-erbB-2)
Tremelimumab744483AstraZenecaanti-CTLA-4 monoclonal anibodyCTLA-4
  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Available Agents was originally published by the National Cancer Institute.”

Email